Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q3 2025 value amounting to $102000.0.

  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges rose 4166.67% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $367000.0, marking a year-over-year decrease of 1678.0%. This contributed to the annual value of $377000.0 for FY2024, which is 1892.74% up from last year.
  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges amounted to $102000.0 in Q3 2025, which was up 4166.67% from $103000.0 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges' 5-year high stood at $128000.0 during Q4 2022, with a 5-year trough of $49000.0 in Q3 2022.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $87000.0 (2021), whereas its average is $87800.0.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges in the last 5 years was 13207.55% (2024), contrasted with its biggest fall of 5203.25% (2024).
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges (Quarter) stood at $87000.0 in 2021, then skyrocketed by 47.13% to $128000.0 in 2022, then dropped by 3.91% to $123000.0 in 2023, then tumbled by 52.03% to $59000.0 in 2024, then surged by 72.88% to $102000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $102000.0 for Q3 2025, versus $103000.0 for Q2 2025 and $103000.0 for Q1 2025.